Market news

Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001. The global, double-blind study randomized 85 participants to […]

2026-09-10. The following slide deck was published by Pharvaris N.V.

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

The company will seek approval for deucrictibant XR as competition in the HAE market mounts.

Pharvaris (PHVS) has an average rating of buy and mean price target of $58.38, according to analysts

Peng Lu, President, on September 08, 2026, sold 15,000 shares in Pharvaris (PHVS) for $610,134. Foll

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results in lung and swelling diseases.

Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline results from its pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant XR for the prevention of hereditary angioedema attacks. The study met its primary endpoint, with once-daily deucrictibant XR producing an 83% reduction in the HAE attack rate compared with placebo.

Pharvaris (PHVS) stock jumps as the company announces a late-stage trial for its lead asset deucrictibant XR, in hereditary angioedema. Read more here.

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types o...

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated...

Pharvaris stock has delivered a strong 103.0% return over the past five years, yet the latest valuation checks and market multiples suggest the shares may now sit on the expensive side rather than offering clear value. Over the last 5 years Pharvaris has returned 103.0%, which sets a high bar for any further upside to be justified by fundamentals. Future growth in revenue and cash flow can support the current price, but execution risk around turning that growth into sustainable profitability...

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Pharvaris (PHVS) has an average rating of Buy and mean price target of $47.15, according to analysts

The FDA agreed to review the company's treatment for a swelling disease.